Yves Vanrenterghem
- Transplantation top 0.01%
- Nephrology top 0.05%
- Surgery top 0.5%
- Pediatrics, Perinatology and Child Health top 0.2%
- Psychiatry and Mental health top 0.5%
- Co-authors
- Dirk KuypersPieter EvenepoelKristin VerbekeBert BammensBart MaesMaarten NaesensBjörn MeijersHylke de Jonge
- Topics
- Renal Transplantation Outcomes and Treatments (139 papers)Organ Transplantation Techniques and Outcomes (50 papers)Pharmacological Effects and Toxicity Studies (46 papers)
- Partner nations
- BelgiumUnited StatesSpain
In The Last Decade
Yves Vanrenterghem
260 papers receiving 12.4k citations
Hit Papers
Peers
Comparison fields: 5 of 147
- Transplantation 5.5k
- Nephrology 3.8k
- Surgery 3.2k
- Pediatrics, Perinatology and Child Health 2.0k
- Psychiatry and Mental health 1.5k
Countries citing papers authored by Yves Vanrenterghem
This map shows the geographic impact of Yves Vanrenterghem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yves Vanrenterghem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yves Vanrenterghem more than expected).
Fields of papers citing papers by Yves Vanrenterghem
This network shows the impact of papers produced by Yves Vanrenterghem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yves Vanrenterghem. The network helps show where Yves Vanrenterghem may publish in the future.
Co-authorship network of co-authors of Yves Vanrenterghem
This figure shows the co-authorship network connecting the top 25 collaborators of Yves Vanrenterghem. A scholar is included among the top collaborators of Yves Vanrenterghem based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yves Vanrenterghem. Yves Vanrenterghem is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 6 | |
| 2 | 3-Year Safety Profile of Belatacept in Kidney Transplant Recipients from the BENEFIT and BENEFIT-EXT Studies | 4 |
| 3 | 4 | |
| 4 | The Pregnane X Receptor (NR1I2) C-25385T Single Nucleotide Polymorphism (SNP) Does Not Affect Tacrolimus Pharmacokinetics in a Large Cohort of Renal Transplant Recipients | 1 |
| 5 | 7 | |
| 6 | Early immunosuppression exposure and incidence of acute rejection and renal function progression: Evidence from the symphony study | 2 |
| 7 | Levels and progression of parameters associated with metabolic syndrome by immunosuppressive regimen: Evidence from the symphony study | 3 |
| 8 | Progression of renal function by donor quality and the modifying effect of immunosuppression: Evidence from the Symphony study | 1 |
| 9 | Belatacept (LEA29Y) as part of a CNI-free regimen in recipients of renal allografts with higher risk of poor long-term function and graft loss: Comparison with cyclosporine A | 5 |
| 10 | Do kidd and duffy blood group antigens play a role as minor histocompatibility antigens in renal allograft rejection | 4 |
| 11 | Adjuvant low dose cidofovir therapy and reduction of immunosuppression for BK polyomavirus interstitial nephritis (BKVIN) in renal recipients | 1 |
| 12 | Posttransplant cardiovascular risk: Impact on long-term patient survival - | 0 |
| 13 | Comparison of standard and low dose tacrolimus in cadaveric kidney transplant recipients | 2 |
| 14 | Cyclosporine therapy for ulcerative colitis does not cause permanent renal damage | 1 |
| 15 | Direct quantitation of oxidized low-density-lipoprotein (oxldl) and assessment of its pole in atherothrombosis in end-stage renal-disease (esrd) patients | 8 |
| 16 | Chronic renal-allograft failure - clinical overview | 19 |
| 17 | Long-term prognostic-significance of the reduction of proteinuria by indomethacin (i) in patients with chronic glomerulonephritis | 1 |
| 18 | A controlled trial of one month versus 3 months cyclosporine and conversion to azathioprine in renal-transplantation | 1 |
| 19 | Are cyclosporine-treated hla-drw6-positive cadaveric kidney allograft recipients high responders | 1 |
| 20 | Fractional clearances of dextran and dextran sulfate in a new model of proteinuria in dog | 1 |
About Yves Vanrenterghem
Yves Vanrenterghem is a scholar working on Transplantation, Nephrology and Pediatrics, Perinatology and Child Health, having authored 267 papers that have together received 12.7k indexed citations. Recurring topics across this work include Renal Transplantation Outcomes and Treatments (139 papers), Organ Transplantation Techniques and Outcomes (50 papers) and Pharmacological Effects and Toxicity Studies (46 papers). The work is most often cited by research in Transplantation (5.5k citations), Nephrology (3.8k citations) and Pediatrics, Perinatology and Child Health (2.0k citations). Yves Vanrenterghem has collaborated with scholars based in Belgium, United States and Spain. Frequent co-authors include Dirk Kuypers, Pieter Evenepoel, Kristin Verbeke, Bert Bammens, Bart Maes, Maarten Naesens, Björn Meijers, Hylke de Jonge, Kathleen Claes and Evelyne Lerut. Their work appears in journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Investigation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.